Patent intelligence · US
US 11975066
Ungulate-derived polyclonal immunoglobulin specific for coronavirus protein and uses thereof
Ungulate-derived polyclonal immunoglobulin specific for coronavirus protein and uses thereof
Patent details — US 11975066
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 7, 2024
- Expiration
- May 2, 2044
- Applicant
- SAB Biotherapeutics, Inc.
- Claims
- 9
- CPC classes
- A61K, A61K2039/505, A61K2039/53, A61K2039/545
Quick answer
US 11975066 (Ungulate-derived polyclonal immunoglobulin specific for coronavirus protein and uses thereof) is held by SAB Biotherapeutics, Inc.. Status: granted. Granted May 7, 2024. Expires May 2, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- SAB Biotherapeutics, Inc.
- Grant date
- Expiration
- Claims
- 9
- CPC classes
- A61K, A61K2039/505, A61K2039/53, A61K2039/545, A61K2039/55566, A61K2039/55577
Frequently asked questions
What is US patent 11975066?
US 11975066 (Ungulate-derived polyclonal immunoglobulin specific for coronavirus protein and uses thereof) is held by SAB Biotherapeutics, Inc.. Status: granted. Granted May 7, 2024. Expires May 2, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11975066?
SAB Biotherapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1 pharmaceutical patents for this assignee.
When does US 11975066 expire?
Our index shows an expiration date of May 2, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.